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Introduction
Etanercept (Enbrel) is effective in the treatment of
rheumatoid arthritis both as monotherapy [1] and in com-
bination with methotrexate (MTX) [2]. Etanercept has
been registered for use in either manner in most coun-
tries. While direct comparisons of etanercept as
monotherapy with etanercept plus MTX have not yet been
reported to date, but are currently being studied in a ran-
domised clinical trial, longitudinal follow-up studies may
provide additional information on the relative strengths of
the two treatment options.
The complex questions that govern clinical decision-
making can rarely be addressed adequately using ran-
domised trials [3]. In such instances, structured
longitudinal follow-up studies may have greater practical
value. We now have at our disposal such a structured
follow-up system for patients being treated with biological
agents in the rheumatic diseases; namely, the Stockholm
TNFα Follow-Up Registry (STURE) of patients treated
with biological agents in Stockholm [4]. We thus wished
to utilise data from this registry to address the question of
whether treatment with etanercept plus MTX was more
efficacious in clinical practice than treatment with etaner-
cept alone.
Materials and methods
The STURE database collects efficacy and safety data for
all patients starting biological treatments at the major hos-
pitals in Stockholm, as part of the nationwide registry of
AntiRheumatic Therapies in Sweden. The assessments
are performed at 0, 3, 6 and 12 months and annually
thereafter. These assessments include the American
College of Rheumatology core outcomes (the 28 swollen
DAS28 = 28-joint count-based disease activity score; EULAR = European League Against Rheumatism; MTX = methotrexate; STURE = Stockholm
TNFα Follow-Up Registry; VAS = visual analogue scale.
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Abstract
Etanercept can be used both as monotherapy and in
combination with methotrexate (MTX), but direct comparisons
of these two options have not yet been reported. In order to
compare the results seen in actual practice between these
two options, clinical data on 97 patients followed in the
Stockholm TNFα Follow-Up Registry were analysed. In 57 of
these patients etanercept was added to previously started
MTX while the others were treated with etanercept alone. The
two groups had similar levels of disease activity at baseline.
After 3 months, a significantly lower mean disease activity
score (28-joint count-based disease activity score) was
attained by the patients on etanercept plus MTX. In this group,
the number of patients achieving European League Against
Rheumatism-defined remission was also significantly greater.
Other disease outcomes showed non-significant trends in the
same direction. These data suggest that the combination of
etanercept plus MTX is clinically more efficacious than
etanercept alone.
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and tender joint count, the visual analogue scale [VAS] for
global health and for pain, the health assessment question-
naire disability index, the erythrocyte sedimentation rate
and C-reactive protein, and the physician’s global assess-
ment of disease activity), the 28-joint count-based disease
activity score (DAS28) [5,6], the record of concurrent med-
ications, the employment status, and the side effects.
While the STURE database is part of the AntiRheumatic
Therapies in Sweden national biologicals safety registry,
the present study was performed using only data collected
and analysed at the Karolinska and Huddinge Hospitals.
The STURE database is maintained in the RAMONA soft-
ware package (Carmona, Halmstad, Sweden). Statistical
analyses were carried out using StatView 5.0.1 for PC
(SAS Institute Inc., Cary, NC, USA).
Results
For the purpose of the present study, data were analysed
on 97 patients with rheumatoid arthritis treated with etaner-
cept, 57 of whom were also treated with MTX. This group of
97 patients represented the first patient cohort in our reg-
istry, and all patients completed at least 6 months of treat-
ment. The decision whether to use etanercept monotherapy
or combination therapy with MTX was based solely on clini-
cal considerations by the responsible physician.
In the case of combination therapy, etanercept was added
to prior treatment with MTX. Patients treated with combi-
nations of other disease-modifying antirheumatic drugs
plus etanercept were not included in this analysis. The
mean MTX dosage in these combination-treated patients
was 12.9 ± 0.4 (range 5–20, median 12.5), and the
patients had received this treatment for at least 3 months.
The baseline values in this patient group thus represent
the definitive although insufficient responses to MTX.
The baseline demographic and disease characteristics of
all patients are presented in Table 1. The patients were
comparable with respect to age, years of disease activity,
rheumatoid factor positivity and shared epitope positivity.
However, a somewhat higher proportion of patients were
female in the group receiving combination therapy. The
baseline disease activity for all patients is presented in
Table 2. As can be seen, the patients receiving combina-
tion therapy had slightly lower disease activity values than
those receiving etanercept alone, but only patient’s
assessment of pain by VAS showed a statistically signifi-
cant difference.
The DAS28 values following the initiation of etanercept
therapy are shown in Fig. 1. A statistically significant
decrease in disease activity is seen following inception of
this therapy. This improvement is maintained during the
2-year follow-up period, consistent with data reported
from clinical trials and other follow-up reports. As can be
seen, while the baseline DAS28 values are similar in the
two groups, patients receiving combination treatment
attain lower DAS28 values at each of the subsequent time
points, and the difference is statistically significant after
3 months. The absolute difference, however, is small.
We also analysed the individual American College of
Rheumatology components after 3 months and after 6
months. As can be seen in Table 3, the patient global
assessment, the patient assessment of pain, and the
physician global assessment all revealed statistically sig-
nificantly better results for the combination therapy as
compared with the monotherapy after 3 months. The other
Table 1
Baseline information on patients
Etanercept plus
methotrexate Etanercept only P value
n 57 40
Age (years) 51.1 ± 1.7 53.3 ± 2.0 Not significant
Female (%) 91 70 < 0.02
Disease (years) 14.5 ± 1.3 12.7 ± 1.5 Not significant
Rheumatoid 95 90 Not significant
factor-positive (%)
Shared 78 87 Not significant
epitope-positive (%)
Values presented as mean ± standard error of the mean. Comparisons
are by unpaired Student t test for continuous variables and by Fisher
exact test for dichotomous variables.
Table 2
American College of Rheumatology core outcomes at baseline
Etancercept plus
methotrexate Etanercept only P value
SJC 10.3 ± 0.8 10.7 ± 1.1 Not significant
TJC 10.6 ± 1.0 11.2 ± 1.2 Not significant
HAQ 1.62 ± 0.08 1.86 ± 0.09 Not significant
Patient global 63.8 ± 3.1 72.2 ± 3.0 Not significant
Patient pain 65.1 ± 2.7 75.5 ± 3.0 < 0.02
Physician global 2.35 ± 0.10 2.49 ± 0.12 Not significant
ESR 32.6 ± 2.7 37.4 ± 3.4 Not significant
Values presented as mean ± standard error of the mean. Comparisons
are by unpaired Student t test. ESR, erythrocyte sedimentation rate;
HAQ, health assessment questionnaire disability index; patient global,
patient assessment of global health by 100 mm visual analogue scale;
patient pain, patient assessment of pain by 100 mm visual analogue
scale; physician global, physician’s assessment of global disease
activity by five-point scale (0–4); SJC, swollen joint count (based on
28 joints); TJC, tender joint count (based on 28 joints).
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outcomes also favoured the combination therapy but did
not reach statistical significance. A similar pattern
emerged after 6 months (Table 4).
The DAS28-based European League Against Rheumatism
(EULAR) response criteria [7] were also compared. As
shown in Fig. 2, the EULAR criteria for moderate/good
response at 3 months and at 6 months did not show sig-
nificant differences between the groups. At 3 months,
however, the percentage of patients that achieved a
EULAR-defined remission was significantly greater in the
combination group than in the etanercept-only group.
Discussion
We analysed the clinical responses to treatment with etan-
ercept either as monotherapy or when added to baseline
therapy with MTX. The present results show that the
DAS28 values after 3 months were significantly better in
the patients receiving combination therapy than in the
etanercept-only patients, as were several of the core out-
comes. A greater proportion achieved an EULAR-defined
remission at 3 months. On the contrary, the absolute dif-
ferences between the various outcomes in the two treat-




Disease activity score (28-joint count-based disease activity score
[DAS28]) (mean ± standard error of the mean [SEM]) in patients with
rheumatoid arthritis treated with etanercept with or without
methotrexate (MTX). At 3 months, a significant difference is seen
between the two groups (by unpaired Student t test).
Table 3
American College of Rheumatology core outcomes at
3 months
Etanercept plus
methotrexate Etanercept only P value
SJC 4.40 ± 0.57 5.56 ± 0.84 Not significant
TJC 4.78 ± 0.73 5.25 ± 0.90 Not significant
HAQ 1.20 ± 0.10 1.50 ± 0.12 Not significant
Patient global 28.0 ± 3.0 45.0 ± 4.0 < 0.001
Patient pain 27.6 ± 3.4 44.2 ± 4.7 < 0.005
Physician global 1.17 ± 0.09 1.55 ± 0.12 < 0.02
ESR 18.6 ± 1.8 22.6 ± 3.0 Not significant
Values presented as mean ± standard error of the mean. Comparisons
are by unpaired Student t test. ESR, erythrocyte sedimentation rate;
HAQ, health assessment questionnaire disability index; patient global,
patient assessment of global health by 100 mm visual analogue scale;
patient pain, patient assessment of pain by 100 mm visual analogue
scale; physician global, physician’s assessment of global disease
activity by five-point scale (0–4); SJC, swollen joint count (based on
28 joints); TJC, tender joint count (based on 28 joints).
Table 4
American College of Rheumatology core outcomes after
6 months
Etanercept plus
methotrexate Etanercept only P value
SJC 3.95 ± 0.65 4.27 ± 0.84 Not significant
TJC 4.85 ± 0.87 4.62 ± 0.77 Not significant
HAQ 1.30 ± 0.1 1.56 ± 0.1 Not significant
Patient global 30.5 ± 4.6 36.4 ± 5.5 < 0.05
Patient pain 29.5 ± 3.5 36.8 ± 4.3 Not significant
Physician global 1.55 ± 0.1 1.17 ± 0.1 < 0.02
ESR 19.4 ± 2.35 25.0 ± 3.31 Not significant
Values presented as mean ± standard error of the mean. Comparisons
are by unpaired Student t test. ESR, erythrocyte sedimentation rate;
HAQ, health assessment questionnaire disability index; patient global,
patient assessment of global health by 100 mm visual analogue scale;
patient pain, patient assessment of pain by 100 mm visual analogue
scale; physician global, physician’s assessment of global disease
activity by five-point scale (0–4); SJC, swollen joint count (based on
28 joints); TJC, tender joint count (based on 28 joints).
Figure 2
Disease activity score (DAS) response/remission after 3–6 months
therapy with etanercept with or without methotrexate (MTX). Data are
the percentages of patients achieving the European League Against
Rheumatism criteria for moderate/good clinical response and for
remission.
Group comparisons of this nature suffer from several
weaknesses that can impact the results. First, the patient
groups may be inherently different due to the lack of ran-
domisation. We identified differences in the gender distri-
bution between the groups, but correcting for this did not
meaningfully change the results (data not shown). Disease
activity parameters at baseline were well balanced in the
two treatment groups, as were some of the known prog-
nostic factors for clinical course (rheumatoid factor and
shared epitope). One important difference between the
two treatment groups, which cannot be eliminated, is the
fact itself that the monotherapy group did not receive
MTX. In all but a few instances this reflected prior treat-
ment with MTX resulting either in treatment-limiting side
effects or in a lack of efficacy. This may reflect on the
nature of the patients’ disease in a matter that cannot be
captured otherwise and may thus have influenced the
results. Specifically, studies by Choi and colleagues [8]
and by Hurst and colleagues [9] have shown that patients
treated with MTX have significant survival benefits com-
pared with those treated with other antirheumatic agents. It
has been suggested that patients with rheumatoid arthritis
who are able to tolerate MTX represent a subset with
better prognosis than those patients who cannot take MTX.
A baseline imbalance also existed with respect to the
patient’s assessment of pain by VAS, which was signifi-
cantly lower in the combination group. This imbalance
weakens the importance of the difference seen in VAS
pain at 3 months, and indeed a statistical comparison of
the changes in VAS pain between the groups was not sig-
nificant. With respect to the main outcome in this study,
the DAS28, it is important to underscore that the VAS
pain is not included in the formula for calculating the
DAS28. In as much as any baseline imbalance in the
outcome of interest would tend to bias towards finding a
greater effect in the group with the higher baseline value
(through regression to the mean [10]), the slightly higher
disease activity indices in the monotherapy group actually
strengthen the association between better treatment
results and combination therapy.
In view of our results with respect to DAS28 values and
the core set of disease activity indices, it was somewhat
surprising that the EULAR criteria for moderate/good
response did not show a difference between the groups
(whereas there was a significant difference for EULAR-
defined remissions). This most probably reflects the small
absolute magnitude of the difference between the DAS28
in the two groups, and confirms that dichotomous out-
comes (responder indices) are less sensitive than continu-
ous outcomes.
We found no differences between the groups with
respect to acute-phase reactants (the erythrocyte sedi-
mentation rate [Table 3] and C-reactive protein revealed
the same patterns [data not shown]). Generally, the
tumour necrosis factor alpha blockers are very effective at
reducing acute-phase reactants, which often normalise
rapidly after initiation of these agents. One possible expla-
nation why this study shows the least differences for the
acute phase reactants could thus be that the effects of
etanercept on this outcome are already maximal, making
an additional effect of MTX much harder to detect.
It is important to underscore that the comparison in this
study is between, on the one hand, etanercept monother-
apy initiated in patients who were not receiving disease-
modifying antirheumatic drug therapy and, on the other
hand, combination therapy where etanercept is added to
established MTX therapy. This situation does not directly
translate into a clinical decision-making point. However,
our results do suggest that, in patients who have an insuf-
ficient clinical response to MTX, the addition of etanercept
to MTX may give better efficacy than instituting etanercept
as monotherapy (i.e. switching from the one drug to the
other). Our result would even suggest that, in patients
receiving etanercept as monotherapy with only partially
satisfactory responses, the addition of MTX might give
additional clinical benefit. While many of these implica-
tions can and probably will be tested through randomised
controlled trials, we believe that our data, derived from
real-life treatment, could play a role of some importance in
guiding physicians’ decision-making processes.
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